Efgartigimod has already been used to treat other autoimmune disorders apart from myasthenia gravis, such as neuromyelitis optic spectrum disorder (14) and anti-LGI1-associated autoimmune encephalitis (15). This evidence concerns the gene LGI1 and myasthenia gravis.